Navigating Multi-Drug Resistant Tuberculosis: A Case Report on Treatment Challenges in a Non-Smoking Male
Abstract
A 39-year-old non-smoker man came in with persistent cough, fever, and significant weight loss over the past 5 months. Having previously been treated for pulmonary tuberculosis, he showed signs of malnutrition and lung crackles upon examination. Sputum tests confirmed active multi-drug resistant tuberculosis (MDR-TB), resistant to isoniazid, rifampicin, ethambutol, and streptomycin. Laboratory results indicated anemia and elevated liver enzymes. Chest imaging revealed cavitary lesions and opacities in the lungs. He was initiated on second-line anti-TB drugs with directly observed therapy. Regular follow-ups were scheduled to monitor his progress, highlighting the complexities of managing MDR-TB and the critical importance of treatment adherence.
Full text article
References
CDCTB: tuberculosis (TB) - drug-resistant TB. centers for disease control and prevention . (2022). Accessed: May 4,2024:https://www.cdc.gov/tb/topic/drtb/default.htm.
Pyle M. 1947. Relative number of resistant tubercle bacilli in sputa of patients before and during treatment with streptomycin. In Proceedings of the staff meetings Mayo Clinic 22: 465 –473.
Prasad R, Gupta N, Singh M : Multidrug-resistant tuberculosis: trends and control. Indian J Chest Dis Allied Sci . 2022, 56:237-46. 10.5005/ijcdas-56-4-237
Suen SC, Bendavid E, Goldhaber-Fiebert JD: Disease control implications of india’s changing multi-drug resistant tuberculosis epidemic. PLoS One. 2014, 9:e89822. 10.1371/journal.pone.0089822
Tiberi S, Utjesanovic N, Galvin J, et al. Drug resistant TB - latest developments in epidemiology, diagnostics and management. Int J Infect Dis. 2022;124 Suppl 1:S20-S25. doi:10.1016/j.ijid.2022.03.026
Guidelines for programmatic management of drug resistant tuberculosis in india . (2021). Accessed: May 5, 2024: https://tbcindia.gov.in/showfile.php?lid=3590.
Drug resistant tb India. TBFacts. (2005). Accessed: May 5, 2024: https://tbfacts.org/about-us/.
D'souza DT, Mistry NF, Vira TS, et al.: High levels of multidrug resistant tuberculosis in new and treatment- failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Public Health. 2009, 9:211. 10.1186/1471-2458-9-211
Paramasivan CN, Venkataraman P: Drug resistance in tuberculosis in india . Indian J Med Res. 2004, 120:377-86.
17. Singla R, Al-Sharif N, Al-Sayegh MO, Osman MM, Shaikh MA: Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia. Int JnTuberc Lung Dis. 2002, 6:585-91.
Paramasivan CN: An overview on drug resistant tuberculosis in india . Ind J Tub. 1998, 45:73-81
Seung, K. J., Keshavjee, S., & Rich, M. L. (2015). Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 5(9), a017863. doi:10.1101/cshperspect.a017863
Arora VK, Sarin R, Singla R, Khalid UK, Mathuria K, Singla N, Myneedu VP: DOTS-Plus for patients with multidrug-resistant tuberculosis in India: early results after three years. Indian J Chest Dis Allied Sci. 2007, 49:75-9.
Akkerman OW, Ter Beek L, Centis R, Maeurer M, Visca D, Muñoz-Torrico M, Tiberi S, Migliori GB. Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients. Int J Infect Dis 2020r;92S:S10–14. doi:10.1016/j.ijid.2020.01.029.
Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, van der Zalm MM,
et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis 2021;25(10):797–813. doi:10.5588/ijtld.21.0425.
Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, Marx FM, Meghji J, Pedrazzoli D, Salomon JA, Sweeney S, van Kampen SC, Wallis RS, Houben RMGJ, Cohen T. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. Lancet Glob Health 2021;9(12):e1679–87. doi:10.1016/S2214-109X(21)00367-3
Allwood BW, Byrne A, Meghji J, Rachow A, van der Zalm MM, Schoch OD. Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Chal-
lenge. Respiration 2021;100(8):751–63.
Hsu D, Irfan M, Jabeen K, Iqbal N, Hasan R, Migliori GB, Zumla A, Visca D, Centis R, Tiberi S. Post tuberculosis treatment infectious complications. Int J Infect Dis 2020;92S:S41–5. doi:10.1016/j.ijid.2020.02.032.
Quaife M, Houben RMGJ, Allwood B, Cohen T, Coussens AK, Harries AD, van Kampen S, Marx FM, Sweeney S, Wallis RS, Menzies NA. Post-tuberculosis mortality and morbidity:valuing the hidden epidemic. Lancet Respir Med 2020;8(4):332–3.
Mpagama SG, Msaji KS, Kaswaga O, Zurba LJ, Mbelele PM, Allwood BW,
Ngungwa BS, Kisonga RM, Lesosky M, Rylance J, Mortimer K. The burden and
determinants of post-TB lung disease. Int J Tuberc Lung Dis 2021;25(10):846–
doi:10.5588/ijtld.21.0278.
Duarte R, Aguiar A, Pinto M, Furtado I, Tiberi S, Lönnroth K, Migliori GB. Different disease, same challenges: Social determinants of tuberculosis and COVID-19.
Pulmonology 2021;27(4):338–44.
Bastian I, Rigouts L, Van Deun A, Portaels F. Directly observed treatment, short-course strategy and multidrug- resistant tuberculosis: are any modifications required?
Bull World Health Organ 2000; 78 : 238-51.
Espinal MA, Dye C, Raviglione M, Kochi A. Rational ‘DOTS plus’ for the control of MDR-TB. Int J Tuberc Lung Dis 1999; 3 : 561-3.
Iseman MD. MDR-TB and the developing world – a problem no longer to be ignored: the WHO announces ‘DOTS Plus’ strategy. Int J Tuberc Lung Dis 1998; 2 :867.